Unilife — Piper Jaffray Healthcare Conference 2014
15 slides from Unilife's conference presentation, Dec 2, 2014

Slide 1: Piper Jaffray Healthcare Conference
Exhibit 99.1 Piper Jaffray Healthcare Conference December 2, 2014 Confidential-Unilife Corporation

Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Thispresentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our manag

Slide 3: Investment Highlights
Investment Highlights Prefilled Syringes Reconstitution Systems Auto-Injectors Wearable Injectors Ocular Systems Novel Systems A broad portfolio of innovative, differentiated, customizable products Injectable drug delivery systems Leveraged by customers to enhance and differentiate injectable therap

Slide 4: A Selection of Unilife Customers
A Selection of Unilife Customers As of Sep 30, 2014 Unilife had 15 active programs* with multiple customers across all product platforms. Most programs remain confidential at this time. 4 Confidential-Unilife Corporation * Includes announced supply agreements

Slide 5: Our Annuity-Like Business Model
Our Annuity-Like Business Model A broad portfolio Long-term Supply direct to of innovative customer supply pharmaceutical product platforms agreements companies Avg. 10-15 year supply Customizable product B2B model with well agreements provide platforms with market- defined list of current and conti

Slide 6: Delivering Brilliance. Together with our Customers.
Delivering Brilliance. Together with our Customers. Creating Value. Minimizing Risk. Addressing Customer Needs. Pharmaceutical or Drug-Device Unilife Biotech Company Combination Product • A broad market-driven • Large portfolios of • Building therapy compliance portfolio of customizable, biologics,

Slide 7: Participating in Large, Fast-Growing Markets
Participating in Large, Fast-Growing Markets Injectable Drug Delivery Systems Device Market Growth* by Segment2015- 2025 Market Segment CAGR * ASP* $18,000 Prefilled Syringes 8% $0.5 -$2 $16,000 (ready-to-fill syringes) $14,000 Wearable Injectors 105% $25-$35 (Wearable, disposable systems) $12,000 R

Slide 8: A Broad, Flexible Portfolio for all Injectable Therapies
A Broad,FlexiblePortfolio for all InjectableTherapies* Unifill® Unifill Finesse™ Unifill Select™ Unifill Allure ™ Unifill Nexus™ AutoMix Presto™ EZMix Genesis™ EZMix Engage™ EZMix Prodigy™ RITA™ LISA™ Precision-Therapy™ Flex-Therapy™ Ocu-mix™ Depot-ject™ Ocu-ject™ Micro-ject™ * Excluding insulin. Pr

Slide 9: Commercial Supply Agreements for Unifill
Commercial Supply Agreements for Unifill ® • Global supply agreement for Lovenox Global supply agreement for initial target list of • • World’s largest selling prefilled drug 20 generics • Supply agreement extending out to 2024 • 15 year duration with 175MM minimum unit purchase volumes • Payments o

Slide 10: Supply Agreements for Wearable Injectors
Supply Agreements for Wearable Injectors 15-Year commercial supply agreement • Long-term commercial supply agreement Unilife sole provider of wearable injectors with biologics R&D arm MedImmune for all Sanofi’s applicable drugs • Unilife to customize and supply devices Platform also offered for mole

Slide 11: The Magnitude of our Supply Agreements
The Magnitude of our Supply Agreements Unifill Unifill Wearable injectors Wearable injectors Finesse platform 15-Years Long-term (not disclosed) 10-Years 15-Years 5-10 biologics* Several biologics Min. 150MM Min. 175MM units^ annually units^ annually Average 5MM units annually per wearable injector

Slide 12: Today's agreement for Depot-ject
Today’s agreement for Depot-ject™ Details of the Agreement Worldwide 10-year commercial supply agreement with global pharmaceutical company for use with approved therapy Treatmentof visionimpairment associatedwith a highprevalencediseaseof the retina Intravitreal injection for sustained release into

Slide 13: A Large, Growing Commercial Pipeline
A Large, Growing Commercial Pipeline Additional agreements generate incremental revenue growth Commercial Active Commercial Pipeline Programs supply •Multiple pharma •11 additional •Initial key and biotech programs* as of Sep agreements inc. companies 30, 2014 •Sanofi (wearable •Many approved •Spann

Slide 14: Scaling up to meet Accelerating Demand
Scaling up to meet Accelerating Demand York, Pennsylvania • 160,000 sq. ft. FDA-registered state-of-the-art manufacturing facility • Commercial supply underway and will accelerate through 2016-2017 • Pre-approval for facility expansion to support accelerating demand Four continents 30 countries • Th

Slide 15: Delivering Brilliance.
Delivering Brilliance. Redefining the Market for Injectable Drug Delivery Systems • The most extensive, market-driven portfolio for injectable therapies • Signing long-term commercial supply agreements with many of the largest, most innovative pharmaceutical and biotech companies • Agreements to gen
Source: SEC EDGAR · 8-K filed Dec 2, 2014
More decks from Unilife Corp
Investor Presentation (November 2016)13 slides · Nov 17, 2016
Q4 and FY2016 Earnings Presentation19 slides · Nov 2, 2016
Earnings Presentation (July 2015)23 slides · Jul 30, 2015
Q2 FY2015 Earnings Presentation15 slides · Feb 12, 2015
Q1 FY2015 Earnings Presentation12 slides · Nov 14, 2014
Shareholder Meeting (November 2014)32 slides · Nov 14, 2014